Update on anti-emetics for chemotherapy-induced emesis

被引：17

作者：

Olver, IN ^{[1
]}

机构：

[1] Univ Adelaide, Royal Adelaide Hosp, Ctr Canc, Adelaide, SA 5000, Australia

来源：

INTERNAL MEDICINE JOURNAL | 2005年 / 35卷 / 08期

关键词：

antiemetic; 5 hydroxytrptamine(3) antagonist; neurokinin(1); antagonist; acute emesis; delayed emesis;

D O I：

10.1111/j.1445-5004.2005.00879.x

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The need to control chemotherapy-induced emesis has stimulated research into anti-emetics. Emesis is not only unpleasant, but negatively impacts on global quality of life. The development of two new classes of drugs has been responsible for the major advances in anti-emesis. The 5 hydroxytryptamine(3) (5HT(3)) antagonists in combination with dexamethasone significantly improved the control of acute post chemotherapy emesis, but delayed emesis which can last for several days was still problematic, yet its incidence was underestimated by clinicians. Both the control of acute and delayed emesis was improved when the neurokinin, (NK1) receptor antagonists were added to 5HT(3) antagonists and steroids. The complete control of delayed emesis was improved by 21% with little toxicity. The triple drug combination has become the standard of care for preventing the emesis associated with cytotoxic drugs of high emetic potential.

引用

页码：478 / 481

页数：4

共 20 条

[1] Effects of aprepitant on the pharmacokinetics of ondansetron and granisetron in healthy subjects [J].

Blum, RA ;

Majumdar, A ;

McCrea, J ;

Busillo, J ;

Orlowski, LH ;

Panebianco, D ;

Hesney, M ;

Petty, KJ ;

Goldberg, MR ;

Murphy, MG ;

Gottesdiener, KM ;

Hustad, CM ;

Lates, C ;

Kraft, WK ;

Van Buren, S ;

Waldman, SA ;

Greenberg, HE .

CLINICAL THERAPEUTICS, 2003, 25 (05) :1407-1419

[2] ON THE RECEIVING END PATIENT PERCEPTION OF THE SIDE-EFFECTS OF CANCER-CHEMOTHERAPY [J].

COATES, A ;

ABRAHAM, S ;

KAYE, SB ;

SOWERBUTTS, T ;

FREWIN, C ;

FOX, RM ;

TATTERSALL, MHN .

EUROPEAN JOURNAL OF CANCER & CLINICAL ONCOLOGY, 1983, 19 (02) :203-208

[3] Patient perceptions of the side-effects of chemotherapy: the influence of 5HT3 antagonists [J].

deBoerDennert, M ;

deWit, R ;

Schmitz, PIM ;

Djontono, J ;

vanBeurden, V ;

Stoter, G ;

Verweij, J .

BRITISH JOURNAL OF CANCER, 1997, 76 (08) :1055-1061

[4] Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist -: Results of a phase III, single-dose trial versus dolasetron [J].

Eisenberg, P ;

Figueroa-Vadillo, J ;

Zamora, R ;

Charu, V ;

Hajdenberg, J ;

Cartmell, A ;

Macciocchi, A ;

Grunberg, S .

CANCER, 2003, 98 (11) :2473-2482

[5] Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron [J].

Gralla, R ;

Lichinitser, M ;

Van der Vegt, S ;

Sleeboom, H ;

Mezger, J ;

Peschel, C ;

Tonini, G ;

Labianca, R ;

Macciocchi, A ;

Aapro, M .

ANNALS OF ONCOLOGY, 2003, 14 (10) :1570-1577

[6] Incidence of chemotherapy-induced nausea and emesis after modern antiemetics - Perception versus reality [J].

Grunberg, SM ;

Deuson, RR ;

Mavros, P ;

Geling, O ;

Hansen, M ;

Cruciani, G ;

Daniele, B ;

De Pouvourville, G ;

Rubenstein, EB ;

Daugaard, G .

CANCER, 2004, 100 (10) :2261-2268

[7]

Herrstedt J, 2004, ANN ONCOL, V15, P218

[8] The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: A multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin - The Aprepitant Protocol 052 Study Group [J].

Hesketh, PJ ;

Grunberg, SM ;

Gralla, RJ ;

Warr, DG ;

Roila, F ;

De Wit, R ;

Chawla, SP ;

Carides, AD ;

Ianus, J ;

Elmer, ME ;

Evans, JK ;

Beck, K ;

Reines, S ;

Horgan, KJ .

JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (22) :4112-4119

[9] Methodology of antiemetic trials: response assessment, evaluation of new agents and definition of chemotherapy emetogenicity [J].

Hesketh, PJ ;

Gralla, RJ ;

du Bois, A ;

Tonato, M .

SUPPORTIVE CARE IN CANCER, 1998, 6 (03) :221-227

[10] Patient-tailored antiemetic treatment with 5-hydroxytryptamine type 3 receptor antagonists according to cytochrome P-450 2D6 genotypes [J].

Kaiser, R ;

Sezer, O ;

Papies, A ;

Bauer, S ;

Schelenz, C ;

Tremblay, PB ;

Possinger, K ;

Roots, I ;

Brockmöller, J .

JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (12) :2805-2811

← 1 2 →